The PennZone

  • Home
  • Non-profit
  • Books
  • Entertainment
  • Music
  • Marketing
  • Health
  • Legal
  • Technology

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Innodata Inc. (INOD) Investors
The PennZone/10261583

Trending...
  • Badanamu Partners With Moonbug Entertainment In Landmark Distribution Deal
  • Mad Darbarian is available for views as a Horror Host
  • UVIFY Brings Advanced Autonomous Systems Research to IROS 2026 in Pittsburgh
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Innodata Inc. ("Innodata" or the "Company") (NASDAQ: INOD) common stock between May 9, 2019 and February 14, 2024, inclusive (the "Class Period"). Innodata investors have until April 22, 2024 to file a lead plaintiff motion.

Investors suffering losses on their Innodata investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

On February 15, 2024, Wolfpack Research published a report alleging, among other things, that Innodata is "a deteriorating, manual data-entry business driven by offshore labor, not innovation." Wolfpack further alleged that "[s]igns that [Innodata] is not an AI company are everywhere" noting the Company's minimal spending on cloud services and R&D, as well as the fact that "96% of [its] workforce is overseas and its average employee generates less than $20k of revenue annually."

More on The PennZone
  • American Garden Rose Selections™ Announces 2027 Winners
  • Crossroads4Hope Launches Blood Cancer Resource Hub
  • Wilson Venture Capital to Launch News Organization; Will Name Trevor Wilson CEO
  • NIL Club Data Shows Brands Are Looking Beyond Follower Counts in College Sports
  • Georgia's Magical Nights of Lights Bigger and Brighter for 2026

On this news, Innodata's stock price fell $3.74, or 30.5%, to close at $8.52 per share on February 15, 2024, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company did not have a viable AI technology; (2) its Goldengate AI platform is a rudimentary software developed by just a handful of employees; (3) it was not going to utilize AI to any significant degree for new Silicon Valley contracts; (4) it was not effectively investing in research and development for AI; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased Innodata common stock, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

More on The PennZone
  • Bicentennial Occult Outing Alternative History Video Series Launches for Spooky Season
  • Harvard Educated Board Certified Endodontist Joins Pearlfection Dentistry
  • NYC Banners Delivers High-Stakes UN General Assembly Backdrop for the US Department of State Event
  • OneVizion Appoints Energy Infrastructure Executive Walt Farrell to Board of Directors
  • Tampa Bay Reporter Launches with a Mission to Deliver Local News with National Reach

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Top 100 Golf Coach Daniel Guest and Imagen Golf Announce Partnership with Remo Golf at Fairways Golf Club
  • DBF Viewer 2000 v9.32 Adds New Control for Data Export
  • Badanamu Partners With Moonbug Entertainment In Landmark Distribution Deal
  • Exonerated Movers Launches in Philadelphia on International Wrongful Conviction Day
  • Atlas Advisors President and Founder Mike McGuire Named a 2026 Leader in Business and Finance by LVB
  • Client 1st Financial Founder Michael Fischer Recognized for Building a Relationship-Rooted Career
  • Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
  • Curtis Salgado shares a love letter to the city of Chicago and Otis Rush with new single
  • Oral statement on the situation of Chairman Lee Man-hee in pretrial detention in the Republic of Korea
  • Names Are Not Important Asks What Remains When Identity Is Stripped of Labels
  • UVIFY Brings Advanced Autonomous Systems Research to IROS 2026 in Pittsburgh
  • Mad Darbarian is available for views as a Horror Host
  • Most Utah Deaths Never Reach the Medical Examiner. Postmortem Pathology Offers Salt Lake City a Private Autopsy Option
  • Virtually Tour Heritage at South Brunswick's Resort-Style Living - Experience Indoor and Outdoor Amenities at Your Fingertips
  • Derek Cook's Roofing Encourages Homeowners to Prepare for Fall Weather
  • Boston Industrial Solutions Expands Product Offering with Pad Printing Pads and Silicone for Custom Pad Manufacturing
  • Rodeo FX Originals Appoints Yvann Thibaudeau Head of Development & IP
  • Phoenix 5/7 Emerges as a Genre-Fluid Artist Collective
  • Massage Revolution Expands to Santa Monica With New Wilshire Boulevard Location
  • "Warrior Defined" Event Brings Men Together in Charlotte, With Calls for Events Across the U.S

Popular on PennZone

  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A!
  • Sea Tales Strengthens U.S. Leadership Team as Retail Expansion Accelerates
  • Lake Norman Philharmonic - Free Community Concert
  • Mandeville Pests May Pose Serious Health Risks for Your Family
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
  • STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
  • Paul Ohana - From Beverly Hills Salon Chair To Beauty Founder Celebrity Hair Expert
  • Garage door installation or repair in Minnesota? Which makes more sense for your family?
  • New Bethany's 35th Annual Souper Day to Spotlight Connection Between Health, Hunger and Housing

Similar on PennZone

  • ResC4EU Final Event at KOMPOZYT-EXPO 2026 – Building Resilient European Supply Chains
  • NIL Club Data Shows Brands Are Looking Beyond Follower Counts in College Sports
  • NYC Banners Delivers High-Stakes UN General Assembly Backdrop for the US Department of State Event
  • Genuine Hospitality, LLC Selected to Operate Fairfield Inn & Suites Tampa Wesley Chapel
  • Pregis to Highlight EPR Expertise, Sustainable Packaging Solutions and Live Automation Demonstrations at Pack Expo International 2026
  • Infinity Infusion Solutions Launches "Women Leading Infusion Care" Campaign for National Women in Business Month
  • HuskyTail Digital Puts AI to Work Behind the Scenes to Cut Client Turnaround Time
  • AI, Real-World Data "RWD" and U.S. Expansion Put Predictive Healthcare in Focus for POMDOCTOR Ltd. (N A S D A Q: POM)
  • $11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc
  • Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us